Capabilities by Industry: Healthcare
Greenhill has considerable transaction experience and a global network of corporate relationships in the Healthcare sector. Our Managing Directors and professionals in North America, the United Kingdom, Continental Europe, Australia and Japan have executed many of the most significant and complex transactions for some of the leading companies in the industry.
In addition to traditional M&A transactions, our team has extensive experience advising on complex partnering and licensing transactions.
Our experience in the Healthcare industry encompasses the following sub-sectors: healthcare services; life science tools; medical devices and services; branded, specialty and generic pharmaceuticals; and biotechnology.
Below we highlight a few of the transactions on which we have advised in this area:
Recent Transactions
Sort By
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Boehringer Ingelheim
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Recepta Biopharma
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Recepta Biopharma on a capital raise
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Allied Healthcare
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Aesynt, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Allergan Generics
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Altegra Health, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Aralez Pharmaceuticals Inc.
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Portfolio of GlaxoSmithKline plc consumer and OTC brands
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Refinancing of syndicated bank debt facilities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
MannKind Corporation
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
![USA/Germany U.S.A., Germany flags](https://www.greenhill.com/sites/default/files/usa_germany.gif)
Siemens Health Services
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Clinuvel Pharmaceuticals Limited
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Forest Laboratories Inc.
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Unfors Raysafe AB
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Fidelis SeniorCare Inc. (Michigan Heath Plan)
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Fidelis SeniorCare Inc., a healthcare provider focused on the care of the elderly, on the sale of a majority of its SecureCare Michigan health plan to Centene Corporation, a managed care provider focused on the Medicaid space
![Ireland Ireland flag](https://www.greenhill.com/sites/default/files/ireland.gif)
Warner Chilcott, plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Coventry Health Care Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Coventry Health Care Inc., a diversified managed health care company that offers a full portfolio of managed care products serving the commercial group and individual, Medicare Advantage, Medicare Part D and Medicaid markets, on its acquisition by Aetna
![South Africa/Switzerland South Africa, Switzerland flags](https://www.greenhill.com/sites/default/files/s-africa_switz_91006.gif)
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
ISTA Pharmaceuticals, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
iNova Pharmaceuticals
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
American Dental Partners, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
![Japan Japan flag](https://www.greenhill.com/sites/default/files/japan.gif)
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Ltd
Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics
![USA/Switzerland U.S.A., Swiss flags](https://www.greenhill.com/sites/default/files/usa_swiss.gif)
Alcon, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company